Targeting signaling pathways to improve treatment for pancreatic cancer
Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
This study is looking at how certain signals in pancreatic cancer cells might help the cancer grow and resist treatment, with the goal of finding new ways to improve care for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project ID | NIH-10883563 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a type of cancer that is often diagnosed at advanced stages and is resistant to standard treatments. The team aims to understand how certain signaling molecules, particularly those involving the STAT3 pathway, contribute to the cancer's growth and resistance to therapy. By using advanced techniques to analyze how these signals operate in both tumor cells and the surrounding immune environment, the researchers hope to identify new therapeutic strategies that can prevent resistance and improve patient outcomes. The study will involve both laboratory models and analysis of human patient samples to validate findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those at advanced stages of the disease.
Not a fit: Patients with early-stage pancreatic cancer or those with other types of cancer may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting similar signaling pathways in other cancers, suggesting that this approach may also be effective in pancreatic cancer.
Where this research is happening
La Jolla, UNITED STATES
- Salk Institute for Biological Studies — La Jolla, United States (Active)
Researchers
- Principal investigator: Hunter, Tony R. — Salk Institute for Biological Studies
- Study coordinator: Hunter, Tony R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.